NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
ID: 351647Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351647

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-101.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention, under a cooperative agreement mechanism (UG3/UH3). This funding opportunity aims to support multi-site exploratory and confirmatory clinical trials, as well as biomarker validation studies, focusing on innovative interventions for stroke prevention, treatment, and recovery. The initiative emphasizes collaboration within the NIH StrokeNet infrastructure, which includes coordinating and data management centers to facilitate recruitment and implementation of studies. Interested applicants must submit their proposals by November 19, 2026, and can find additional information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-101-Full-Announcement.html
    PAR-24-101.html
    The Department of Health and Human Services is issuing a Notice of Funding Opportunity (NOFO) inviting applications for NIH StrokeNet Clinical Trials aimed at stroke treatment, recovery, and prevention. Supported by the National Institutes of Health (NIH) and the National Institute of Neurological Disorders and Stroke (NINDS), this funding opportunity seeks multi-site exploratory and confirmatory clinical trials alongside biomarker validation studies. Successful applicants will work within the NIH StrokeNet infrastructure, which includes coordinating and data management centers, providing infrastructure for recruitment and implementation of studies. The NOFO utilizes a bi-phasic UG3/UH3 cooperative agreement mechanism, with an initial one-year planning phase followed by a potential six-year implementation phase based on milestone achievement. Applications must detail their project management and milestones, and eligibility includes various organizations and institutions, emphasizing diversity among applicants. Funds are contingent on appropriations, with budgets reflecting the actual needs of proposed projects. The call for proposals aims to advance research in stroke therapeutic innovations, emphasizing collaborative efforts among public and private entities within the NIH StrokeNet network.
    Similar Opportunities
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that address critical questions related to neurological disorders, focusing on studies involving drugs, biologics, devices, and early interventions. The program emphasizes rigorous research design and encourages diverse and innovative research teams, with grants potentially spanning up to five years, beginning with a planning phase before transitioning to execution. Interested applicants can find more information and application details at the provided link, with a submission deadline of March 10, 2025, and no cost-sharing or matching requirement.
    NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated efficacy clinical trials through the NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) program. This initiative aims to support clinical studies that evaluate drugs, biologics, devices, and various interventions targeting neurological disorders, requiring a phased approach where UG3 planning must precede UH3 execution. The trials must be well-designed with robust scientific rationale and diverse participant inclusion, emphasizing collaboration with patient advocacy groups and national networks. Interested applicants can find more information and application guidelines at the provided NIH link, with a submission deadline of January 9, 2025, and no cost-sharing or matching requirements. For inquiries, contact the NIH OER Webmaster at grantsinfo@nih.gov.
    Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for prospective observational comparative effectiveness research (CER) in clinical neurosciences, specifically through the National Institute of Neurological Disorders and Stroke (NINDS). This initiative aims to encourage grant applications that investigate preventive strategies, diagnostic approaches, and various interventions, including drugs, devices, and therapies, that align with NINDS's mission. The funding mechanism follows a UG3/UH3 cooperative agreement structure, starting with a 2-year planning phase (UG3) that may transition into a 5-year observational study phase (UH3) upon meeting specific milestones. Interested applicants, including a diverse range of organizations, must submit their applications by May 7, 2025, and can find more information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the SIREN Neurologic Clinical Trials (UG3/UH3), aimed at developing multi-center clinical trials focused on neurological emergencies. This initiative encourages applications from a diverse range of entities, including universities, nonprofit organizations, and various community-serving institutions, to utilize the SIREN Network's infrastructure for efficient trial management, statistical support, and patient recruitment. The overarching goal is to enhance understanding and treatment of neurological emergencies through collaborative clinical research, ultimately improving patient outcomes and advancing healthcare practices. Interested applicants should note that the application deadline is March 6, 2026, and can find further details and guidelines at the provided NIH link or contact grantsinfo@nih.gov for inquiries.
    Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for a funding opportunity titled "Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)," aimed at enhancing clinical trial methodologies for Functional Neurological Disorders (FNDs). This initiative seeks to address critical challenges in the diagnosis and management of FNDs by encouraging the validation of biomarkers and clinical outcome assessments (COAs) that are specifically tailored for clinical trials. Given the significant healthcare burden posed by FNDs, which often require interdisciplinary approaches for effective management, this funding opportunity emphasizes the need for robust clinical evidence to improve treatment strategies and patient outcomes. Interested applicants, including a diverse range of organizations such as higher education institutions and community-based organizations, must submit their proposals by November 5, 2024, with funding contingent on NIH appropriations. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the clinical validation of candidate biomarkers for neurological and neuromuscular disorders through the U44 Cooperative Agreement mechanism. This initiative aims to rigorously validate biomarkers that have already been identified and for which detection methods have been developed, ensuring compliance with FDA guidelines to establish their clinical sensitivity and specificity. This program is crucial for advancing therapeutic development in the field of brain health, with funding potentially reaching $700,000 for Phase I and $1.5 million for Phase II projects. Interested applicants must adhere to specific submission guidelines and deadlines, with the application closing on June 22, 2026. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-096.html.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)" under Funding Opportunity Number PAR-24-097. This initiative aims to clinically validate candidate biomarkers for neurological diseases, focusing on establishing their clinical sensitivity and specificity, provided that preliminary conditions such as detection method development are met. The program emphasizes the importance of multidisciplinary collaborations and requires applicants to include a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research teams. Interested applicants must submit their proposals by February 22, 2024, with project durations capped at five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-097.html.
    The NINDS Human Cell and Data Repository (U24 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NINDS Human Cell and Data Repository (U24 - Clinical Trial Not Allowed)" aimed at supporting the National Institute of Neurological Disorders and Stroke (NINDS) in maintaining and expanding its repository of human cell lines, specifically fibroblast and induced pluripotent stem cells (iPSCs). The initiative seeks to facilitate basic and translational research in neurological disorders by generating new cell lines, ensuring quality assessment standards, and distributing these resources to qualified researchers globally. With a total funding commitment of approximately $1.4 million for fiscal year 2025, eligible applicants include a wide range of organizations, such as educational institutions and non-profits, while proposals focused on non-human cell resources are excluded. Interested parties must submit their applications by October 17, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small business concerns (SBCs) through the NINDS Exploratory Clinical Trials program (R43/R44), aimed at supporting investigator-initiated exploratory clinical trials related to neurological disorders. This program invites applications for studies that evaluate drugs, biologics, devices, or therapies, generating preliminary data to inform future clinical development, with a focus on enhancing diverse perspectives within research teams. Eligible U.S.-based SBCs can apply for funding caps of up to $295,924 for Phase I and $1,972,828 for Phase II, with applications due by September 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html.
    Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)." This initiative aims to promote the discovery and early evaluation of candidate biomarkers that can facilitate the clinical development of neurotherapeutics and their application in clinical practice, focusing on both animal studies and preliminary human evaluations. The funding is structured as a phased R61/R33 award, where the R61 phase emphasizes proof-of-concept studies using human samples, while the R33 phase focuses on clinical validation for specified uses. Interested applicants, including various educational and community organizations, must submit their proposals by May 7, 2025, and can find additional details and application guidelines at the provided NIH link. For inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.